G, Wassmann B, et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 2005;23:7583-93. 8. Dazzi F, Szydlo RM, Craddock C, Cross NC, Kaeda J, Chase A, et al. Comparison of single-dose and ...

The presence of the common acute lymphoblastic leukemia antigen (CALLA) on leukemic cells from the great majority of patients with non-T cell acute lymphoblastic leukemia and chronic myelogenous leukemia in blast crisis suggests that CALLA could be differentiation antigen expressed by normal lymphoid and myeloid stem cells. Treatment with a murine monoclonal anti-CALLA antibody and complement l...

Acute myeloid leukemia is a clonal neoplasm derived from myeloid progenitor cells with a varying outcome. The initial goal of treatment is the achievement of complete remission, defined for over 40 years by morphology. However, without additional post-remission treatment the majority of patients relapse. In many cases of acute myeloid leukemia, allogeneic stem cell transplantation offers the be...

The BCR-ABL1 oncoprotein transforms pluripotent HSCs and initiates chronic myeloid leukemia (CML). Patients with early phase (also known as chronic phase [CP]) disease usually respond to treatment with ABL tyrosine kinase inhibitors (TKIs), although some patients who respond initially later become resistant. In most patients, TKIs reduce the leukemia cell load substantially, but the cells from ...

A case is described of acute leukemia whose neoplastic cells possessed myeloid and lymphoid characteristics. Neoplastic cells possessed cytoplasmic granules containing Sudan black B material and diaminobenzidine myeloperoxidase. In addition, these luekemic cells were positive for terminal deoxynucleotidyl transferase. Ia antigen, and the common acute lymphocytic leukemia antigen. These findings...

Chronic myeloid leukemia (CML) is an excellent model of the multistep processes in cancer. Initiating BCR-ABL mutations are required for the initial phase of the disease (chronic phase, CP-CML). Some CP-CML patients acquire additional mutation(s) that transforms CP-CML to poor prognosis, hard to treat, acute myeloid or lymphoid leukemia or blast phase CML (BP-CML). It is unclear where in the he...

Chronic myeloid leukemia (CML) is a clonal disease characterized by the presence of Philadelphia chromosome and its oncogenic product, BCR-ABL, which activates multiple pathways involved in cell survival, growth promotion, progression. We recently reported that signal-transducing adaptor protein 1 (STAP-1) upregulated CML stem cells (LSCs) functions to reduce apoptosis LSCs upregulating STAT5-d...

Myeloid sarcoma is an extramedullary tumor of malignant myeloid cells often associated with acute myeloid leukemia, chronic myeloproliferative disorders and myelodysplastic syndromes. The skin is one of the most commonly affected sites. We report a rare case of cutaneous myeloid sarcoma associated with chronic myeloid leukemia.

Disease Myelodysplastic syndrome (21 cases), Acute Myeloid Leukemia (5 cases), Chronic Myelomonocytic Leukemia (1 case). Phenotype/cell stem origin Thrombopenia (90%) with anemia (60%). Dysplastic changes in bone marrow: dyserythropoeisis associated with dysgranulopoieisis and/or dysmegakaryocytopoeisis. Epidemiology The frequency of ider(20q) is estimated at 0.49% in myelodysplastic syndrome a...